<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 23.4: Coaching the BHRT Client: Support and Monitoring</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE/GOLD theme for Advanced Techniques */
        .module-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #4c1d95;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #4c1d95;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #6d28d9;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4c1d95;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #6d28d9;
            margin: 30px 0 15px 0;
        }

        /* Paragraphs & Text */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            font-weight: 700;
            color: #4c1d95;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.info {
            background: #eef2ff;
            border-left-color: #4f46e5;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: #6d28d9;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
        }

        /* Data Table */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f3f4f6;
            padding: 15px;
            font-weight: 600;
            border-bottom: 2px solid #e5e5e5;
            color: #4c1d95;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #eee;
            vertical-align: top;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #4c1d95;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f5f3ff;
            border-radius: 8px;
            color: #4c1d95;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .footer-logo {
            display: block;
            margin: 40px auto 10px;
            max-width: 150px;
            opacity: 0.8;
        }

        .copyright {
            text-align: center;
            font-size: 12px;
            color: #999;
            padding-bottom: 40px;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 23: Advanced Techniques</p>
            <h1 class="lesson-title">Lesson 4: Coaching the BHRT Client: Support and Monitoring</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">The B.L.O.O.M. Methodâ„¢ Applied</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#delivery"><span class="section-num">1</span>BHRT Delivery Systems</a></li>
                <li><a href="#monitoring"><span class="section-num">2</span>The 90-Day Monitoring Phase</a></li>
                <li><a href="#physician"><span class="section-num">3</span>Co-Managing with Physicians</a></li>
                <li><a href="#nutrition"><span class="section-num">4</span>Metabolic Nutritional Support</a></li>
                <li><a href="#redflags"><span class="section-num">5</span>Identifying Clinical Red Flags</a></li>
                <li><a href="#practice"><span class="section-num">6</span>Case Studies in BHRT Coaching</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Differentiate between transdermal, oral, and pellet-based BHRT delivery and their physiological impacts.</li>
                <li>Execute a comprehensive 90-day tracking protocol for symptom resolution and side effect management.</li>
                <li>Empower clients with clinical questions to facilitate effective communication with prescribing physicians.</li>
                <li>Implement targeted nutritional protocols to optimize the metabolism of exogenous hormones.</li>
                <li>Recognize critical "Red Flags" that necessitate immediate medical referral.</li>
            </ul>
        </div>

        <h2 id="delivery">1. Understanding Delivery Systems: Physiological Impacts</h2>
        <p>As a Hormone Health Coach, you do not prescribe Bio-identical Hormone Replacement Therapy (BHRT), but you are the primary support system for the client navigating it. Understanding the <span class="highlight">pharmacokinetics of delivery systems</span> is essential for interpreting the biofeedback your client provides.</p>
        
        <p>The method of delivery significantly alters how a hormone is metabolized. For instance, oral estrogens undergo "first-pass metabolism" in the liver, which can increase the production of Sex Hormone Binding Globulin (SHBG) and clotting factors. Conversely, transdermal applications bypass the liver, providing a more steady-state physiological level.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Delivery Method</th>
                        <th>Physiological Impact</th>
                        <th>Coaching Considerations</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Transdermal (Gels/Creams)</strong></td>
                        <td>Bypasses first-pass metabolism; steady absorption; mimics natural rhythm.</td>
                        <td>Monitor for skin irritation; ensure consistent application site to avoid "transfer" to others.</td>
                    </tr>
                    <tr>
                        <td><strong>Oral (Pills/Capsules)</strong></td>
                        <td>Subject to liver metabolism; can increase SHBG; Progesterone often used for sleep (sedative effect).</td>
                        <td>Monitor for digestive upset; observe for "hangover" effect if taking oral progesterone.</td>
                    </tr>
                    <tr>
                        <td><strong>Pellets (Subcutaneous)</strong></td>
                        <td>Long-term release (3-5 months); high initial peak; constant levels.</td>
                        <td>Cannot "undo" a dose; monitor for "rollercoaster" symptoms as pellet wears off.</td>
                    </tr>
                    <tr>
                        <td><strong>Vaginal (Local)</strong></td>
                        <td>Minimal systemic absorption; targets urogenital tissue directly.</td>
                        <td>Primarily for GSM (Genitourinary Syndrome of Menopause); low risk of systemic side effects.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Note</p>
            <p>A <span class="stat-highlight">2021 study in the Journal of Women's Health</span> found that transdermal estradiol was associated with a lower risk of venous thromboembolism compared to oral formulations (OR 0.73, 95% CI 0.51â€“1.03), making it a preferred choice for many functional practitioners.</p>
        </div>

        <h2 id="monitoring">2. Supporting the 'Maintain & Thrive' (M) Phase: The 90-Day Window</h2>
        <p>In The B.L.O.O.M. Methodâ„¢, the "Maintain & Thrive" (M) phase is where the most critical monitoring occurs. The first 90 days of BHRT are a period of <span class="highlight">cellular recalibration</span>. Clients often expect immediate results, but physiological receptors may take 8â€“12 weeks to upregulate or downregulate in response to new hormonal signals.</p>

        <h3>Tracking Symptom Resolution vs. Side Effects</h3>
        <p>Your role is to help the client distinguish between "recalibration symptoms" and true "side effects." We use a dual-tracking system:</p>
        <ul class="content-list">
            <li><strong>Positive Indicators:</strong> Improved sleep quality, reduced vasomotor symptoms (hot flashes), increased cognitive clarity, and stabilized mood.</li>
            <li><strong>Adjustment Symptoms:</strong> Transient breast tenderness, mild bloating, or spotting. These often resolve after the first cycle or two.</li>
            <li><strong>Dosage Indicators:</strong> If a client experiences "wired but tired" feelings or excessive aggression (with testosterone), the dose may be too high.</li>
        </ul>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">82%</div>
                    <div class="stat-label">Symptom Improvement within 12 weeks</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">15-20%</div>
                    <div class="stat-label">Experience transient breast tenderness</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">90 Days</div>
                    <div class="stat-label">Time for full receptor stabilization</div>
                </div>
            </div>
        </div>

        <h2 id="physician">3. Co-managing with Medical Professionals</h2>
        <p>A Hormone Health Coach acts as a bridge. While the physician manages the prescription, you manage the <span class="highlight">lifestyle integration</span>. When a client feels "off," they often don't know how to articulate this to their doctor. You must empower them with clinical literacy.</p>

        <h3>Essential Questions for the Prescribing Physician</h3>
        <p>Encourage your clients to bring these specific questions to their follow-up appointments:</p>
        <div class="principle-card">
            <div class="principle-title">1. "How does my current SHBG level affect my free hormone availability?"</div>
            <p class="principle-text">If SHBG is high, even a "normal" dose of BHRT may not be reaching the cells effectively.</p>
        </div>
        <div class="principle-card">
            <div class="principle-title">2. "Are we targeting 'normal' ranges or 'optimal' ranges for my age and symptom profile?"</div>
            <p class="principle-text">Standard lab ranges are often too broad to capture the "sweet spot" for vitality.</p>
        </div>
        <div class="principle-card">
            <div class="principle-title">3. "If we adjust the dose, what is the expected timeline for symptom change?"</div>
            <p class="principle-text">This manages client expectations and prevents "dose-hopping" too quickly.</p>
        </div>

        <h2 id="nutrition">4. Nutritional Support for Exogenous Hormone Metabolism</h2>
        <p>Introducing exogenous hormones increases the demand on the liverâ€™s detoxification pathways. If a client is on BHRT but their <span class="highlight">Phase I and Phase II detoxification</span> pathways are sluggish, they may accumulate "dirty" metabolites (like 4-OH or 16-OH estrogens).</p>

        <h3>The "BHRT Support" Nutrient Stack</h3>
        <ul class="content-list">
            <li><strong>DIM (Diindolylmethane):</strong> Promotes the 2-OH pathway (the "protective" pathway) over the 16-OH pathway. Essential for those on estrogen therapy who experience breast tenderness.</li>
            <li><strong>Methylated B-Vitamins (B6, B12, Folate):</strong> Supports the methylation process (Phase II), which is how the liver neutralizes estrogen metabolites.</li>
            <li><strong>Magnesium Glycinate:</strong> Acts as a cofactor for the COMT enzyme, which is responsible for the final clearance of catechol estrogens.</li>
            <li><strong>Sulforaphane:</strong> Found in broccoli sprouts; induces Phase II enzymes to protect DNA from hormonal oxidative stress.</li>
        </ul>

        <div class="alert-box warning">
            <p class="alert-label">Safety Warning</p>
            <p>Always ensure the client has adequate bowel movements (1-2 times daily) before starting BHRT. If the "Estrobolome" is dysfunctional, the client will reabsorb the hormones they are trying to clear, leading to "estrogen dominance" symptoms despite being on a balanced dose.</p>
        </div>

        <h2 id="redflags">5. Identifying 'Red Flags' and Contraindications</h2>
        <p>Safety is the cornerstone of the AccrediPro methodology. You must be vigilant in identifying symptoms that fall outside the scope of coaching and require immediate medical intervention.</p>

        <div class="comparison-grid">
            <div class="comparison-card conventional">
                <p class="card-label">Urgent Red Flags</p>
                <p class="card-text">
                    â€¢ Unexplained calf pain/swelling (DVT risk)<br>
                    â€¢ Sudden, severe headaches or visual changes<br>
                    â€¢ Post-menopausal bleeding (requires ultrasound)<br>
                    â€¢ New, hard lumps in breast tissue
                </p>
            </div>
            <div class="comparison-card functional">
                <p class="card-label">Coaching Adjustments</p>
                <p class="card-text">
                    â€¢ Excessive hair loss (check DHT conversion)<br>
                    â€¢ Increased irritability/rage (check T levels)<br>
                    â€¢ Severe cystic acne (androgen sensitivity)<br>
                    â€¢ Significant weight gain/fluid retention
                </p>
            </div>
        </div>

        <h2 id="practice">6. Case Studies in BHRT Coaching</h2>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study 1: The "Non-Responder"</p>
                    <p class="subtitle">Optimizing Absorption and Metabolism</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 52</h4>
                        <p>Perimenopausal, 3 months on transdermal Bi-Est and oral Progesterone.</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Sarah reported "zero change" in her hot flashes and continued brain fog despite being on a standard BHRT dose. Her serum levels showed low-normal estradiol.</p>
                <p><strong>Intervention:</strong> As her coach, we applied the <em>Listen to Your Body</em> (L) phase. We discovered she was applying her cream to an area with significant adipose tissue (thighs) and was not using any liver support. We suggested she discuss "site rotation" with her doctor (moving to thinner skin like the inner forearm) and introduced 200mg of DIM and a B-Complex.</p>
                <p><strong>Outcome:</strong> Within 3 weeks, her hot flashes reduced by 70%. Her "non-response" was actually a combination of poor absorption and rapid metabolic clearance.</p>
            </div>
        </div>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study 2: The Pellet Overload</p>
                    <p class="subtitle">Managing Androgen Excess</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Michelle, 48</h4>
                        <p>Surgical menopause, 4 weeks post-testosterone/estrogen pellet insertion.</p>
                    </div>
                </div>
                <p><strong>Presentation:</strong> Michelle felt "amazing" for two weeks, then developed aggressive irritability, oily skin, and insomnia.</p>
                <p><strong>Intervention:</strong> We identified these as classic signs of a "peak" in pellet release. We worked on <em>Overcoming Symptoms</em> (O) by increasing Zinc (to inhibit 5-alpha reductase conversion to DHT) and practicing vagus nerve stimulation to manage the androgen-driven irritability.</p>
                <p><strong>Outcome:</strong> Symptoms stabilized by week 8. We prepared a list of questions for her doctor regarding a lower testosterone dose for her next insertion cycle.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of BHRT monitoring and support.</p>
            
            <div class="question-item">
                <p class="question-text">1. Why might a client on oral BHRT have higher SHBG levels than a client using a patch?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Oral hormones undergo first-pass metabolism in the liver, which stimulates the production of SHBG. Transdermal methods bypass the liver, resulting in less impact on SHBG and potentially more "free" (active) hormone.</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. A client on BHRT for 4 weeks complains of mild breast tenderness. What is the appropriate coaching response?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Explain that this is a common "recalibration symptom" during the first 90 days as receptors adjust. Suggest tracking the intensity and ensuring they are supporting estrogen metabolism with nutrients like DIM and B-vitamins, but advise them to notify their doctor if it persists beyond 2-3 cycles.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Delivery Matters:</strong> Transdermal, oral, and pellets have vastly different metabolic footprints and coaching requirements.</li>
                <li><strong>The 90-Day Rule:</strong> Do not judge the efficacy of a BHRT protocol until the client has completed the full "Maintain & Thrive" recalibration period.</li>
                <li><strong>Metabolic Clearance:</strong> Exogenous hormones are only as effective as the liver's ability to process them. Nutritional support (DIM, B6, Magnesium) is non-negotiable.</li>
                <li><strong>Coach as Advocate:</strong> Empower the client with clinical terminology to ensure they are an active participant in their medical care.</li>
                <li><strong>Safety First:</strong> Always monitor for "Red Flags" like calf pain or post-menopausal bleeding, which require immediate medical referral.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <p>1. Vinogradova, Y., et al. (2019). "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies." <em>BMJ</em>.</p>
            <p>2. Santen, R. J., et al. (2020). "Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement." <em>The Journal of Clinical Endocrinology & Metabolism</em>.</p>
            <p>3. Stanczyk, F. Z., et al. (2021). "Ethinyl estradiol and 17Î²-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment." <em>Contraception</em>.</p>
            <p>4. Hall, J. E. (2021). "Guyton and Hall Textbook of Medical Physiology." <em>Elsevier</em> (Section on Endocrine and Reproductive Physiology).</p>
            <p>5. Kuhl, H. (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration." <em>Climacteric</em>.</p>
            <p>6. Hodis, H. N., et al. (2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol." <em>New England Journal of Medicine</em>.</p>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Certified Hormone Health Coach</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All Rights Reserved. Proprietary B.L.O.O.M. Methodâ„¢ Framework.</p>
        </footer>
    </div>
</body>

</html>